8-K: Gossamer Bio Receives Nasdaq Delisting Notice Due to Low Share Price

Gossamer Bio has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement for continued listing.

Summary

• Gossamer Bio received a notice from Nasdaq on September 11, 2024, stating that its common stock did not maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
• This failure to meet the minimum bid price requirement puts Gossamer Bio at risk of being delisted from the Nasdaq Global Select Market.
• The company has until March 10, 2025, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If compliance is not achieved by March 10, 2025, Gossamer Bio may be eligible for an additional 180-day compliance period if it transfers its listing to the Nasdaq Capital Market and meets other listing requirements.
• The company may consider options such as a reverse stock split to regain compliance, but there is no guarantee that it will be successful.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting notice) and uncertainty about the company's ability to regain compliance, leading to a low sentiment score.

Positives

• The company has been granted a 180-day period to regain compliance with the minimum bid price requirement.
• There is a possibility of an additional 180-day compliance period if the company transfers to the Nasdaq Capital Market.

Negatives

• The company's stock price has fallen below the minimum bid price of $1.00, triggering a delisting notice from Nasdaq.
• There is no guarantee that the company will be able to regain compliance with the minimum bid price requirement.
• The company may be delisted from the Nasdaq Global Select Market if it fails to regain compliance.

Risks

• The company faces the risk of being delisted from the Nasdaq Global Select Market if it cannot regain compliance with the minimum bid price requirement.
• There is no assurance that the company will be able to successfully appeal a delisting determination.
• The company's stock price may continue to decline if investors lose confidence in its ability to regain compliance.

Future Outlook

The company intends to monitor its stock price and consider options to regain compliance, but there is no guarantee of success.

Management Comments

• The company intends to monitor the closing bid price of its Common Stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement.

Industry Context

Delisting notices are not uncommon for companies that experience a significant drop in their stock price, and this situation highlights the importance of maintaining investor confidence and meeting listing requirements.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face challenges in maintaining their stock price above the minimum bid price requirement.
• Companies like Geron Corporation and Agenus Inc. have faced similar delisting risks in the past due to low stock prices.
• The 180-day compliance period is a standard procedure for Nasdaq-listed companies facing delisting due to low stock prices.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment.
• The company's reputation may be negatively impacted.
• Employees may experience uncertainty about the company's future.

Next Steps

• The company will monitor its stock price.
• The company may consider options to regain compliance, such as a reverse stock split.
• The company may need to transfer its listing to the Nasdaq Capital Market if it fails to regain compliance by March 10, 2025.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, stock price, reverse stock split, listing requirements